Media
Listen to biotech experts on VibeCast
Listen NowAs Seen
%201.webp)
%202.webp)
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
“Although rare diseases impact so many, capacity-constrained biotech and pharma companies have to prioritize which diseases to tackle. Vibe Bio is uniquely solving this problem through cryptocurrency tokens. Through its token, Vibe is able to raise funds and empower patients and scientists to direct those resources to the highest potential drug programs.”
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
"The experience stuck with Tayi, who is a scientist and entrepreneur, and
led him to co-found a new organization that’s designed to allow patients,
scientists, and other experts to have a say in financing rare disease drug
development. The organization, Vibe Bio, launched on Wednesday with
$12 million in seed funding."
“There actually ends up being a myriad of different candidate medicines with promise that are sitting on shelves today, but simply lack the capital and the focus to be able to develop them.”
“Through his own personal and professional experience, Alok has realized that the families of patients with rare diseases have plenty of hope - but what they need is help. Not necessarily finding the right potential therapeutic option - but actually funding it. That’s where the Vibe community steps in - vetting out which drug development programs have the highest potential. ”
“The company [Vibe Bio] has launched two biotech companies in partnership with two foundations: Chelsea’s Hope, which is focused on Lafora disease, a fatal form of progressive myoclonus epilepsy, and NF2 BioSolutions, which hopes to accelerate a gene therapy for neurofibromatosis Type 2, which causes the growth of noncancerous tumors in the nervous system.”
“Alok Tayi is the founder and CEO of Vibe Bio. Vibe Bio is a community of patients, scientists, and partners committed to identifying, funding and developing promising treatments to rare diseases and empowering patient communities with unprecedented ownership over the process.”
“Tayi started Vibe Bio to transform drug development for patients wirh rare diseases, with part financing, part online coordination hub. [...] for example there is a patient advocacy organization dedicated to curing something called Lafora disease, which is a fatal form of progresive epilepsy, Vibe Bio is helping them launch New Hope Therapeutics.”
